Seagen, With Two Big Pharma Bidders, Nearly Lost Both
Seagen was being pursued by another prospective big pharma buyer when it engaged Pfizer in merger negotiations, but both bidders walked away in late summer 2022; Pfizer returned in January.
You may also be interested in...
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
As demand for Wegovy busts through capacity, Biogen’s Viehbacher asks if we need to spend on drugs for weight loss or other preventable diseases when the dollar could go towards non-preventable chronic diseases. Discussing investments at a recent conference, he was joined by Fidelity’s Rajiv Kaul who said the concept of therapeutic classes is outdated
In this week's podcast edition of Five Must-Know Things: Merck & Co’s Prometheus deal; Lilly’s US mirikizumab rejection; Moderna and Merck’s mRNA cancer vaccine shows promise; how SeaGen nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.